Senses Disorder TRIZ Cases

A nucleic acid complex uses a carrier peptide to facilitate endosomal escape of bioactive nucleic acids.

Fluorine-substituted indazoles stimulate soluble guanylate cyclase to treat cardiovascular diseases without nitric oxide tolerance.

Self-assembling cyclosporine nanoemulsion resolves solubility and stability contradictions by maintaining narrow particle distribution.

Novel tricyclic compounds address abnormal kinase activity by targeting Jak1, Jak2, and Tyk2 to treat proliferative disorders.

Neramexane treats severe mast cell diseases by blocking NMDA receptors to prevent mediator release and tissue damage.

Anti-FcRn antibodies block FcRn binding to accelerate IgG catabolism, replacing invasive plasmapheresis while avoiding bleeding risks.

Biodegradable polymer matrices release terpenoid derivatives over one week, resolving insufficient drug retention in posterior eye treatments.

A polynucleotide encoding the PFKFB2 kinase domain modulates glycolytic pathways to enhance glucose entry into photoreceptor cells.

Topical activated vitamin D3 ointment suppresses meibomian gland atrophy, addressing undermanaged ocular discomfort and lipid overaccumulation.

Topical MEK inhibitors stimulate PAX6 expression, reducing fibroblast reproduction and VEGF pathway stimulation to resolve corneal scarring.

Selective sEH inhibitors prevent epoxyeicosatrienoic acid degradation, maintaining vasodilatory effects for cardiovascular treatment.

Zinc and gallium desferrioxamine complexes treat immune disorders by reducing side effects via targeted iron chelation.

Enriched stem cells deliver healthy mitochondria to resolve therapeutic outcome bottlenecks in ocular disease treatment.

A biodegradable hydrophilic hydrogel incorporates dispersed lipophilic particles to extend therapeutic agent release time.

Inhaled indolinone compounds reduce systemic toxicity while maintaining lung efficacy for idiopathic pulmonary fibrosis treatment.

Bifidobacterium lactis BL-04 reduces respiratory illness incidence, duration, and severity in healthy physically active adults.

Submicron cyclosporine A emulsion improves aqueous solubility and ocular residency while reducing irritation from preservatives.

Sequential aqueous and ethanol extraction isolates C-phycocyanin, phytochrome, and lipophilic components from Aphanizomenon flos-aquae.

Curved flow paths reduce pressure drop while enhancing oxygen microbubble infusion rates.

Segmenting the composition into distinct functional layers prevents evaporation and extends tear film breakup time in dry eye patients.

A preservative-free ophthalmic emulsion containing latanoprostene bunod reduces intraocular pressure and promotes optic nerve head blood velocity.

Topical verteporfin and red laser light induce corneal collagen cross-linking, avoiding UVA-induced endothelial damage.

Recombinant AAV9 vectors deliver CLN6 polynucleotides to preserve retinal photoreceptor layers in Batten disease models.

Multi-functional antibody inhibits VEGF binding to neuropilin-1, resolving therapeutic gaps left by conventional anti-VEGF agents.

Small molecule 1,2-bis-sulfonamide derivatives replace unstable peptides to reduce inflammation and cell infiltration in the eye.

Far-infrared and microwave drying preserves amnion tissue structure for long-term storage.

Selective multi-receptor targeting reduces gastrointestinal toxicity and asthma exacerbation risks associated with traditional non-selective NSAIDs.

Specific compounds modulate TRPA1 ion channels to reduce injury severity, addressing the lack of effective agents for chemical warfare exposure.

Alkaline pH control prevents esterification degradation, enabling effective taste-masking without bitterness.

Cladribine reduces lymphocyte levels via metabolic disruption, lowering relapse frequency without broad immunosuppression side effects.

PEGylated GLP-1 agonist NLY01 extends therapeutic duration in the eye.

Complement antagonists modulate C3aR and C5aR signaling to inhibit uncontrolled cell growth in atherosclerosis and cancer while preserving tissue repair.

Segmenting Cathepsin K inhibitors into functional regions addresses drug development complexity while preserving bone density.

A povidone-iodine and N-acetylcysteine eye drop composition reduces bacterial and viral infection counts while maintaining tolerable comfort levels.

A recombinant adeno-associated virus vector delivers the CRB2 gene to restore retinal function and preserve structural integrity in mouse models.

Anti-EphB4 antibodies inhibit EphB4 activity by competing with ligands, resolving insufficient inhibition in cancer therapy.

Pharmaceutical compounds modulate beta-glucocerebrosidase activity to increase enzyme levels in the brain.

A defined fatty acid mixture modulates inflammatory cells to reduce pro-inflammatory mediator release without chronic side effects.

Controlling the pH to 5.2 or lower prevents polymer degradation in non-aqueous formulations, ensuring long-term viscosity stability for hyperhidrosis treatment.

IL-17 antagonists neutralize pro-fibrotic activity, reducing inflammatory mediator secretion and treating renal fibrosis.

C-terminal steric modification boosts peptide inhibitory capacity below 1000 nM, resolving low oral efficacy bottlenecks.